Scholarlink

Background <p>Bariatric surgery and pharmacotherapy represent two major strategies for the treatment of obesity. Sleeve gastrectomy (SG) is the most widely performed surgical procedure and is supported by long-term evidence, while semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has recently emerged as an effective medical therapy. However, prospective real-world studies directly comparing these interventions are limited.</p> Methods <p>We conducted a prospective, non-randomized trial at a single tertiary center (ChiCTR2300070632). Adults with obesity were allocated to SG (<i>n</i> = 36) or once-weekly semaglutide (<i>n</i> = 35) based on shared decision-making. Semaglutide was administered for a planned duration of 24&#xa0;weeks, after which continuation or discontinuation was determined by patient preference. Primary outcomes were percentage total weight loss (%TWL) and changes in body mass index (BMI) at 1, 3, 6, and 12&#xa0;months. Secondary outcomes included changes in metabolic parameters.</p> Results <p>SG achieved significantly greater weight loss at all time points. At 12&#xa0;months, mean %TWL was 28.6% for SG versus 11.3% for semaglutide (<i>p</i> &lt; 0.001). Mean BMI decreased from 32.7 ± 2.8 to 23.8 ± 2.6&#xa0;kg/m<sup>2</sup> in the SG group and from 32.0 ± 2.6 to 28.4 ± 4.0&#xa0;kg/m<sup>2</sup> in the semaglutide group (<i>p</i> &lt; 0.001). Both groups demonstrated metabolic improvements, but SG was associated with greater reductions in triglycerides and greater increases in high-density lipoprotein cholesterol (HDL-C). Among patients who discontinued semaglutide after 6&#xa0;months (<i>n</i> = 25), mean weight increased from 74.6 ± 11.3 to 83.2 ± 12.3&#xa0;kg by 12&#xa0;months, with 32% regaining to baseline weight or higher.</p> Conclusions <p>SG achieved greater weight loss and improvements in triglycerides and HDL-C compared with semaglutide. Semaglutide was effective during treatment, but many patients experienced weight regain after discontinuation.</p> Trial registration <p>Trial Registry No. ChiCTR2300070632 (2023 April 19).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月22日

查看全文
  • Yutung Yen,
  • Qian Zhang,
  • Shiyi Yin,
  • Yujie Pu,
  • Ke Song,
  • Xiaohai Song,
  • Xiaoding Shen,
  • Qianyi Wan,
  • Rui Zhao,
  • Guixiang Zhang,
  • Zhong Cheng,
  • Jason Widjaja,
  • Haiyang Chen,
  • Yi Chen

摘要

Background

Bariatric surgery and pharmacotherapy represent two major strategies for the treatment of obesity. Sleeve gastrectomy (SG) is the most widely performed surgical procedure and is supported by long-term evidence, while semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has recently emerged as an effective medical therapy. However, prospective real-world studies directly comparing these interventions are limited.

Methods

We conducted a prospective, non-randomized trial at a single tertiary center (ChiCTR2300070632). Adults with obesity were allocated to SG (n = 36) or once-weekly semaglutide (n = 35) based on shared decision-making. Semaglutide was administered for a planned duration of 24 weeks, after which continuation or discontinuation was determined by patient preference. Primary outcomes were percentage total weight loss (%TWL) and changes in body mass index (BMI) at 1, 3, 6, and 12 months. Secondary outcomes included changes in metabolic parameters.

Results

SG achieved significantly greater weight loss at all time points. At 12 months, mean %TWL was 28.6% for SG versus 11.3% for semaglutide (p < 0.001). Mean BMI decreased from 32.7 ± 2.8 to 23.8 ± 2.6 kg/m2 in the SG group and from 32.0 ± 2.6 to 28.4 ± 4.0 kg/m2 in the semaglutide group (p < 0.001). Both groups demonstrated metabolic improvements, but SG was associated with greater reductions in triglycerides and greater increases in high-density lipoprotein cholesterol (HDL-C). Among patients who discontinued semaglutide after 6 months (n = 25), mean weight increased from 74.6 ± 11.3 to 83.2 ± 12.3 kg by 12 months, with 32% regaining to baseline weight or higher.

Conclusions

SG achieved greater weight loss and improvements in triglycerides and HDL-C compared with semaglutide. Semaglutide was effective during treatment, but many patients experienced weight regain after discontinuation.

Trial registration

Trial Registry No. ChiCTR2300070632 (2023 April 19).